On Friday, Shares of Eli Lilly and Co (NYSE:LLY), added 0.76% and closed at $82.09 in the last trading session. The last trading range of the stock ranges between $81.30 and $82.31. The company’s Market capitalization is $90.99 Billion with the total Outstanding Shares of 1.10 Billion. During the 52-week trading session the minimum price at which share price traded, registered at $67.88 and reached to max level of $88.16. Eli Lilly and Company (LLY) will present data from several studies which further reinforce the advancement of its diverse clinical cancer portfolio during the European Society of Medical Oncology’s (ESMO) 2016 Congress in Copenhagen, October 7-11. Presentations include new data on abemaciclib, a CDK 4 and CDK 6 inhibitor, and olaratumab, a PDGFRα blocking antibody that recently received a positive CHMP opinion, in addition to data on: pemetrexed, a multi-targeted antifolate; ramucirumab, a VEGF Receptor 2 antagonist; necitumumab, an EGFR blocking antibody; and prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor. Of these presentations, four are featured in late-breaking abstracts (two on abemaciclib, and one each on pemetrexed and ramucirumab).
The presentations on pemetrexed, ramucirumab and necitumumab include data from a few of Lilly’s immuno-oncology clinical collaborations with Merck (known as MSD outside the U.S. and Canada) in trials that are evaluating these molecules in combination with Merck’s pembrolizumab. Notably, the first results from KEYNOTE-021G – which studied pembrolizumab in combination with pemetrexed-plus-carboplatin contrast to pemetrexed-plus-carboplatin alone for the first-line treatment of patients with advanced nonsquamous non-small cell lung cancer regardless of PD-L1 expression – will be featured in the Presidential Symposium on October 9.
Lilly’s data at the ESMO 2016 Congress highlight the ongoing progress in expanding the potential of its portfolio molecules in addition to the advancement of its clinical pipeline. These presentations underscore the company’s multi-faceted strategy in developing cancer treatments – to produce a diverse portfolio of novel agents that attack tumor cell growth and progression in multiple ways to improve patient outcomes. Specifically, this is a balanced approach based on three scientific pillars of tumor cell growth and progression:
Tumor cell signaling: Therapies that target cell signaling to interrupt the communication system that facilitates cancer cells to coordinate their basic activities;
Tumor microenvironment: Treatments attacking the tumor microenvironment which work by reducing the flow of nutrients and mitogens that support and feed tumor cells; and
Immuno-oncology: Therapies that use the patient’s own immune system to fight cancer.
Williams Companies Inc (NYSE:WMB), dropped -0.43% and closed at $30.38 in the last trading session. The last trading range of the stock ranges between $30.31 and $30.73. The company’s Market capitalization is $22.69 Billion with the total Outstanding Shares of 750.66 million. During the 52-week trading session the minimum price at which share price traded, registered at $10.22 and reached to max level of $44.21. Williams (WMB) and Williams Partners (WPZ) plan to report third-quarter 2016 financial results before the market opens on Monday, Oct. 31.
The company and the partnership plan to host a joint Q&A live webcast on Monday, Oct. 31 at 9:30 a.m. EDT. A limited number of phone lines will be available at (888) 364-3105. International callers should dial (719) 325-2228. The conference ID is 6961753.
On the otherhand Mastercard Inc (NYSE:MA), dropped -0.67% and closed at $102.65 in the last trading session. The last trading range of the stock ranges between $101.98 and $103.49. The company’s Market capitalization is $112.08 Billion with the total Outstanding Shares of 1.08 Billion. During the 52-week trading session the minimum price at which share price traded, registered at $78.52 and reached to max level of $103.49. Mastercard recently makes it even easier for developers to create next-generation commerce solutions with the launch of Mastercard Developers.
This single gateway facilitates Mastercard partners to access a diverse range of Application Programming Interfaces (APIs) across payments, data and security. The platform also includes a ‘New and Experimental’ API category that facilitates partners to test new technologies and applications.
The experimental APIs, developed at the company’s eight R&D Labs around the world, will assist partners build, scale and facilitate payments on new platforms. At the same time, they will have a foundation to explore payments integration into new categories such as augmented reality, virtual reality and the Internet of Things.
“We see Mastercard Developers as empowering our customers, partners and their developers in their efforts to innovate and grow their own businesses,” said Oran Cummins, senior vice president for APIs at Mastercard. “The new platform will serve as a key way to integrate Mastercard technology and services into their digital solutions in an easy and cost-effective way. And, consumers will benefit from the simpler, faster and safer experiences driven by these efforts.”